Browsing Tag
ASX biotechnology
1 post
Neuren Pharmaceuticals (ASX: NEU) begins first-ever Phase 3 trial in Phelan-McDermid syndrome
Neuren Pharmaceuticals Limited has dosed the first patient in the first Phase 3 Phelan-McDermid syndrome trial. See why it matters for rare disease drug development.